1. Caffeine citrate for apnea of prematurity—One dose does not fit all a prospective study
- Author
-
Marwan Hanna, Tzipora Strauss, Camilia Taran, Havatzelet Yarden-Bilavsky, Itai Gueta, Ronen Loebstein, and Chava Rosen
- Subjects
business.industry ,Obstetrics and Gynecology ,Gestational age ,medicine.disease ,Caffeine citrate ,Anesthesia ,Pediatrics, Perinatology and Child Health ,Cohort ,medicine ,Population study ,Gestation ,Dosing ,Prospective cohort study ,business ,Apnea of prematurity ,medicine.drug - Abstract
BACKGROUND Caffeine citrate is the most frequently used medication in preterm neonates for the prevention of apnea of prematurity. There is no accepted consensus regarding the optimal caffeine citrate dosing. In this study, we evaluate clinical responses of premature neonates to standard-dose caffeine citrate treatment. METHODS A prospective observational study conducted at the NICU at Sheba Medical Center (3/2016-2/2017). The study population included preterm neonates born at a gestational age (GA)
- Published
- 2021